Skip to content

Examination of Class I HLA-Fc Fusion Proteins in Targeting Cognate Antibody-Producing Cells.

2026 · Methods in molecular biology · Vol 3053, pp. 323-342 · 0 citations
Medicine

TL;DR

The protocols in this chapter outline the design, production, and evaluation of HLA-Fc proteins, emphasizing their efficacy in vitro and in immunodeficient mouse models, potentially providing new therapeutic approaches for managing HLA-sensitized patients in clinical practice.

View source

Similar papers

2026

Modeling the Application of Chimeric Antigen Receptor T Cell Therapy to Eliminate Alloantibodies in Mice.

Method for producing murine CAR T cells, their functional assessment in vitro, as well as their application in an in vivo transplant model, and methods for studying CAR T function in vitro using a cytotoxicity assay and in vivo using an islet transplant model.

C. Markmann, Vijay G. Bhoj · 0 citations
Aug 2026

Immunoglobulin constant domains as targets for T-cell receptor-based treatment of multiple myeloma.

Despite major progress with chimeric antigen receptor (CAR) T-cell therapy, multiple myeloma (MM) remains largely incurable, and most patient relapse. To broaden therapeutic options and overcome antigen escape, we explored T-cell receptor (TCR)-based targeting of intracellular antigens derived from immunoglobulin (Ig)...

M. Meeuwsen, A. Wouters, Johannes C. Wellershoff et al. · 0 citations
Aug 2026

CAR T Cells Targeting an Intracellular Leukemia Antigen Promiscuously Presented by Diverse HLA-II Alleles.

A CAR T-cell approach targeting an intracellular oncoprotein WT1 presented across diverse HLA-II families is developed, establishing a framework for CAR therapies against intracellular antigens, extending potential CAR T-cell applications to new cancer types and patient populations.

Evey Y F Zheng, Chung-Hsi Wang, T. Ochi et al. · 0 citations
Open access Sep 2026

Generation of a highly versatile TCR bispecific scaffold optimized for targeting tumor-specific peptide-HLA antigens

ABSTRACT Redirection of T lymphocytes toward cancer cells has been one of the most promising treatment concepts in oncology developed over the past years and leading to multiple regulatory approvals for both adoptive cell therapy (ACT) and T-cell-engaging bispecific (TEB) molecules. However, progress has been achieved...

M. Hofmann, F. Unverdorben, M. Pszolla et al. · 0 citations
Review Open access Aug 2026

Emerging therapeutic opportunities targeting nonclassical MHC-I molecules.

The biology, disease-associated functions, and therapeutic targeting of nonclassical MHC-I molecules are synthesized, integrating immune checkpoint blockade, antibody-based therapeutics, and MR1- and CD1-restricted cellular immunotherapies into a unified framework.

Yan-Ruide Li, Yu-Ning Chen, Li-Li Yang · 0 citations
Open access Sep 2026

Discovery and engineering of bispecific TCR-mimic antibodies targeting peptide–HLA complex

An integrated platform for generating human antibodies that mimic T-cell receptors and recognize peptide-HLA complexes with high specificity and affinity is developed, demonstrating superior performance compared to competitors’ TCRm antibodies.

Jennifer Watkins-Yoon, Wei-Cheng Lu, E. Petrunak et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.